PCVX Company Profile and Key Details

Vaxcyte, Inc. has 129.82 million shares outstanding. The public float is 116.97 million shares, elevated short interest at 9.86% of float. This equals 11.44 million shares. The short ratio is 8.72 days. Institutional investors hold 115.69% of the float. Insiders own 0.66%. Wassil Jim holds 160.74 thousand shares, PICKERING GRANT has 136.22 thousand shares and GUGGENHIME ANDREW has 109.49 thousand shares. Over the past six months, insider transactions show net selling. They sold 30.42 thousand shares across 8 transactions.

Vaxcyte, Inc. generated EPS of -$5.71 over the past year. Five-year average earnings growth is -26.39%. Wall Street analysts project EPS growth of -1.24% annually over the next five years. The latest quarter delivered EPS of -$1.80. The next quarter is forecast at -$1.74. Next year's EPS is expected at -$28.04. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $116.00 to $38.00. The high target offers 102.66% upside. The low target suggests -33.61% downside. The mean target is $82.00. This offers 43.26% upside. Vaxcyte, Inc. earnings surprise history is a mixed track record. The quarter that ended February 24, 2026, missed forecasts by 17.67%. The prior quarter beat by 22.83%. Over the last six quarters, Apple has recorded several small beats. These include -15.31% in November 05, 2024.

Vaxcyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.40. This means the shares are trading below this model’s fair value.

Vaxcyte, Inc. (NASDAQ:PCVX) closed at $58.42 USD, gaining $1.49 (2.63%) from the previous close of $56.93. The stock is currently mid-range between its 52-week high and low $28.09 and $65.00. With a market capitalization of about $8.44 billion, Vaxcyte, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.39). Key stats such as the average daily volume over the past year has been around 1.25 million shares, volume is running light vs its 52-week average. Headquartered in San Carlos, CA, Vaxcyte, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Grant E. Pickering, the company employs approximately 414 people and listed since June 12, 2020. Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases.

Vaxcyte, Inc. trades at a P/E ratio of -10.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.88 suggesting the stock is closer to book value. The P/FCF stands at -12.24, also below market averages.

Our AI price prediction model suggests that Vaxcyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.57%, with price expected at $53.48 by May 14, 2026, within a range of $51.01 to $55.57 3-Month Outlook: Projected rise of 343.54%, reaching $253.88 by July 29, 2026, with a range of $250.25 to $261.59. 1-Year Outlook: Projected loss of -20.93%, with price at $45.26 by April 30, 2027, within a range of $38.58 to $55.11.

Vaxcyte, Inc. (NASDAQ:PCVX) shares are flat 2.99% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Vaxcyte, Inc. trading at a premium to the broader market with a P/E of -10.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $93.28, suggesting 62.96% upside. Our AI forecast model points to short-term weakness (-6.57% over two weeks), a medium-term rise (343.54% over three months), and a longer-term loss (-20.93% over one year), with expected trading ranges indicating moderate volatility.